Ibogaine and Brain Injury: Could This Plant Medicine Change the Future of PTSD, Depression, and Concussion Recovery?

For many people living with traumatic brain injury (TBI), post-concussion syndrome, PTSD, or severe depression, there comes a point when the standard treatment path begins to feel painfully familiar.

For some, these treatments are life-changing. For others, they provide only modest relief — or none at all. This has led researchers, clinicians, veterans, and patients alike to ask an important question:

What if we've overlooked therapies that deserve serious scientific attention?

One of the most intriguing is ibogaine, a naturally occurring plant-derived medicine that has gained increasing interest for its potential role in treating addiction, PTSD, depression, and traumatic brain injury. Although ibogaine is currently classified as a Schedule I controlled substance in the United States, interest in its therapeutic potential has grown rapidly. Researchers are investigating its possible role in treating addiction, PTSD, depression, and traumatic brain injury, while several states — including Texas — have begun investing in research to better understand its safety and clinical applications. The stories emerging from veterans and athletes have been difficult to ignore.

A Journey Born from Desperation

When I interviewed Lorna Sturchio, a former Navy combat veteran and transformational trauma recovery coach, one thing became immediately clear: she wasn't advocating for ibogaine because of theory. She was advocating because of lived experience.

Lorna served two deployments before suffering a spinal injury, a traumatic brain injury, and military sexual trauma. Like many veterans, she returned home carrying invisible wounds that conventional medicine struggled to heal. Over the years she cycled through numerous medications — including antidepressants, stimulants, anti-anxiety medications, and painkillers — while continuing to battle PTSD, chronic pain, depression, and suicidal thoughts.

Despite years of therapy and medication, nothing created lasting change. Eventually, after surviving a suicide attempt, she reached a turning point. Rather than giving up, she decided to explore a path she had never imagined taking. That path led her to ibogaine.

What Is Ibogaine?

Ibogaine is a naturally occurring alkaloid extracted from the root bark of the Tabernanthe iboga shrub, a plant native to West Africa where it has been used ceremonially for generations.

Unlike many psychedelic compounds that primarily influence serotonin signaling, ibogaine appears to interact with multiple neurotransmitter systems, including dopamine, serotonin, norepinephrine, glutamate, GABA, and opioid receptors. Researchers continue to investigate these mechanisms, which may help explain why the medicine has generated interest across such diverse conditions, including addiction, PTSD, depression, and neurological injury. Its pharmacology is unusually complex, and many questions remain unanswered — but that complexity is also one reason scientists are paying attention.

More Than a Psychedelic Experience

Ibogaine is often grouped under the broad label of "psychedelics," but Lorna believes that description misses something important. She describes the experience as being fundamentally inward.

While some psychedelic experiences are characterized by expansive sensory perception, ibogaine often leads people into a deeply introspective review of their own lives. Many people report revisiting memories, examining long-held beliefs, or viewing difficult experiences from entirely new perspectives. Others describe it less as hallucination and more as a prolonged state of profound reflection.

Rather than simply altering perception, many participants describe ibogaine as creating an opportunity to reorganize their relationship with themselves.

Why Researchers Are Interested in Brain Injury

Although ibogaine research remains in its early stages, several aspects make it particularly interesting for people recovering from traumatic brain injury. Many individuals with persistent post-concussion syndrome also struggle with:

• Depression
• Anxiety
• PTSD
• Sleep disruption
• Emotional dysregulation
• Cognitive fatigue
• Autonomic nervous system dysfunction

These symptoms often reinforce one another, creating a cycle that becomes increasingly difficult to escape. During our conversation, Lorna described seeing veterans and athletes report improvements not only in mood but also in sleep, memory, balance, tremors, and overall cognitive function following treatment. These are personal observations rather than definitive scientific conclusions, but they mirror the kinds of outcomes researchers are beginning to investigate more formally.

The Importance of Preparation and Integration

One of the biggest misconceptions about ibogaine is that it works like a miracle cure. Lorna was careful to push back against that idea. She repeatedly emphasized that ibogaine is a catalyst — not a magic pill.

At the clinic where Lorna works in Cancun, participants undergo extensive medical screening before treatment, including blood work, a 12-lead electrocardiogram (ECG), and continuous cardiac monitoring.

The psychological work also extends far beyond the treatment itself. Participants spend weeks preparing beforehand, receive coaching during their stay, and continue structured integration afterward to help translate insights into lasting behavioral change. That emphasis on integration may be one of the most important lessons from this conversation. Transformation rarely happens because of a single event — it happens because new experiences are supported by new habits.

Why This Conversation Matters

One of the things I appreciated most about speaking with Lorna was her balanced perspective. She doesn't portray ibogaine as a cure-all. She acknowledges that it isn't appropriate for everyone. She openly discusses its medical risks. And she emphasizes the importance of proper screening, preparation, and ongoing support.

At the same time, she challenges us to ask difficult questions:

That doesn't mean abandoning scientific skepticism. It means applying it fairly.

A Turning Point in Research

Momentum around ibogaine research has accelerated in recent years. In 2025, Texas approved a $50 million initiative to support research into ibogaine as a potential treatment for opioid use disorder and other neurological and psychiatric conditions — one of the largest public investments in psychedelic medicine to date. Advocacy organizations continue working toward standardized protocols and carefully designed clinical trials that could eventually determine where ibogaine fits within evidence-based medicine.

Whether ibogaine ultimately becomes part of mainstream neurological and psychiatric care remains to be seen. But one thing is already clear: the conversation has changed.

Hope Requires Curiosity

As someone who works with people recovering from concussion every day, I've learned that healing often begins when we're willing to ask better questions. Sometimes those questions lead us toward new rehabilitation strategies. Sometimes they lead us toward overlooked physiological systems. And sometimes they challenge us to reconsider treatments that were once dismissed before adequate research had the chance to catch up.

Ibogaine may become one of those treatments. The evidence is still evolving. But for people who have exhausted conventional options — and for researchers committed to improving care for brain injury, PTSD, and depression — it is a conversation worth having, and a field worth studying.